See more : KPIT Technologies Limited (KPITTECH.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Sigyn Therapeutics, Inc. (SIGY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sigyn Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Daiwa Securities Group Inc. (8601.T) Income Statement Analysis – Financial Results
- Cohn Robbins Holdings Corp. Red (CRHC-WT) Income Statement Analysis – Financial Results
- PT Indocement Tunggal Prakarsa Tbk (INTP.JK) Income Statement Analysis – Financial Results
- IJJ Corporation (IJJP) Income Statement Analysis – Financial Results
- Shun Ho Holdings Limited (0253.HK) Income Statement Analysis – Financial Results
Sigyn Therapeutics, Inc. (SIGY)
About Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc. operates as a development-stage therapeutic technology company. It offers Sigyn Therapy, a blood purification technology to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the cause of hospital deaths. The company also engages in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; CytoVesicles; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. The company is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 143.32K | 28.35K | 1.28M | 1.80M | 29.21K | 43.15K |
| Cost of Revenue | 8.86K | 10.45K | 536.05 | 11.30K | 35.67K | 9.71K | 512.38K | 1.03M | 9.93K | 25.25K |
| Gross Profit | -8.86K | -10.45K | -536.05 | -11.30K | 107.66K | 18.64K | 771.80K | 770.92K | 19.28K | 17.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 75.12% | 65.74% | 60.10% | 42.72% | 66.00% | 41.49% |
| Research & Development | 798.17K | 657.66K | 734.01K | 27.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.66M | 1.49M | 1.27M | 888.27K | 613.78K | 977.39K | 2.67M | 1.77M | 2.23M | 399.88K |
| Selling & Marketing | 392.00 | 457.00 | 0.00 | 705.00 | 11.83K | 45.95K | 533.45K | 795.82K | 42.99K | 5.57K |
| SG&A | 1.66M | 1.49M | 1.27M | 888.98K | 625.62K | 1.02M | 3.21M | 1.48M | 2.27M | 405.45K |
| Other Expenses | 0.00 | 0.00 | -536.05K | 0.00 | 0.00 | 105.27K | 3.21M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.46M | 2.15M | 2.01M | 916.43K | 625.62K | 1.02M | 3.21M | 1.48M | 2.27M | 405.45K |
| Cost & Expenses | 2.46M | 2.15M | 2.01M | 916.43K | 661.28K | 1.03M | 3.72M | 2.51M | 2.28M | 430.70K |
| Interest Income | 0.00 | 782.55 | 460.36 | 343.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.04M | 646.74K | 399.07K | 343.16K | 55.20K | 352.84K | 790.84K | 52.77K | 441.18K | 0.00 |
| Depreciation & Amortization | 8.86K | 10.45K | 19.15K | 11.30K | 75.33K | 247.39K | 235.79K | 86.46K | 1.16K | 0.00 |
| EBITDA | -2.45M | -2.14M | -2.53M | -905.13K | -442.63K | -1.70M | -2.82M | -549.42K | -691.62K | -387.54K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -308.84% | -2,671.50% | -171.20% | -34.56% | -7,710.39% | -898.05% |
| Operating Income | -2.46M | -2.15M | -2.01M | -916.43K | -517.96K | -1.00M | -2.43M | -710.20K | -2.25M | -387.54K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -361.39% | -3,544.18% | -189.56% | -39.36% | -7,714.35% | -898.05% |
| Total Other Income/Expenses | -1.69M | -782.55K | -996.40K | -343.16K | -2.80M | -1.30M | -1.41M | -121.33K | -80.13K | 0.00 |
| Income Before Tax | -4.15M | -2.93M | -3.00M | -1.26M | -3.31M | -2.30M | -4.25M | -831.53K | -2.69M | -387.54K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -2,311.58% | -8,129.24% | -330.99% | -46.08% | -9,224.88% | -898.05% |
| Income Tax Expense | 0.00 | 782.11K | 399.07K | 343.16K | -183.12K | 800.00 | 800.00 | 3.00 | 0.00 | 0.00 |
| Net Income | -4.15M | -3.71M | -3.40M | -1.60M | -3.13M | -2.62M | -4.25M | -831.53K | -2.69M | -387.54K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -2,183.82% | -9,243.24% | -331.05% | -46.08% | -9,224.88% | -898.05% |
| EPS | -3.77 | -3.97 | -0.09 | -0.22 | -5.78 | -6.04 | -13.54 | -114.92 | -11.77 | -2.08 |
| EPS Diluted | -3.77 | -3.97 | -0.09 | -0.22 | -5.78 | -6.04 | -13.54 | -114.92 | -11.77 | -2.08 |
| Weighted Avg Shares Out | 1.10M | 934.00K | 36.40M | 7.35M | 541.84K | 433.82K | 313.97K | 7.24K | 228.83K | 186.35K |
| Weighted Avg Shares Out (Dil) | 1.10M | 934.00K | 36.40M | 7.35M | 541.84K | 433.82K | 313.97K | 7.24K | 228.83K | 186.35K |
Sigyn Therapeutics Featured on National Public Radio: “Addressing the Cytokine Storm”
SAN DIEGO, CA, Aug. 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions precipitated by cytokine storm syndrome, announced today that Tech Nation...
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit
San Diego, California--(Newsfile Corp. - August 23, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 4:15 PM ET
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit
San Diego, California--(Newsfile Corp. - August 17, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation
Sigyn Therapeutics, Inc. Announces Participation in the Q3 Virtual Investor Summit
San Diego, California--(Newsfile Corp. - August 16, 2021) - Sigyn Therapeutics, Inc. (OTC Pink: SIGY) today announced that Jim Joyce, Chairman & CEO will be attending the Q3 Virtual Investor Summit. Event Q3 Investor Summit Date August 17-18th, 2021 Presentation August 17th at 4:15 PM ET
Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets
SAN DIEGO, CA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of sepsis and other life-threatening inflammatory conditions, today released the following note authored by...
Sigyn Therapeutics Announces Successful Completion of Animal Pilot Study
SAN DIEGO, CA, July 29, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of life-threatening inflammatory conditions, today announced the completion of a pilot animal study that validated the feasibility of...
Podcast Corner - Chairman, CEO of Sigyn Therapeutics, Inc. Discusses Treatment of Life-Threatening Conditions Induced by Cytokine Storm Syndrome
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - January 25, 2021) - Investorideas.com, a global news source and leading retail investor and trader resource issues a new CEO interview for the Podcast Corner. In today's special edition, Investor Ideas...
Source: https://incomestatements.info
Category: Stock Reports